USA flag logo/image

An Official Website of the United States Government

Company Information:

Name: MANDALMED, INC.
Address: 665 3rd Street
Suite 250
SAN FRANCISCO, CA 94107-1953
Located in HUBZone: No
Woman-Owned: Yes
Minority-Owned: No
Phone: N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $1,973,613.00 9
SBIR Phase II $749,980.00 1
STTR Phase I $125,000.00 1

Award List:

GALECTIN 1 FOR MULTIPLE SCLEROSIS

Award Year / Program / Phase: 1999 / SBIR / Phase I
Agency: HHS
Principal Investigator: Deborah E. Hall
Award Amount: $135,801.00

N/A

Award Year / Program / Phase: 2000 / SBIR / Phase I
Agency: HHS
Principal Investigator: Deborah E. Hall
Award Amount: $142,130.00

Novel Treatment for Breast Cancer: Truncated Galectin-3

Award Year / Program / Phase: 2001 / SBIR / Phase I
Agency: HHS
Principal Investigator: Constance M. John
Award Amount: $236,893.00
Abstract:
DESCRIPTION (provided by applicant): Despite the available treatments breast cancer ranks second as the cause of death from cancer in women primarily due to metastases of the primary tumor to other sites in the body. We will extend our… More

NOVEL EX VIVO GENE THERAPY FOR SPINAL CORD INJURY

Award Year / Program / Phase: 2002 / SBIR / Phase I
Agency: HHS
Principal Investigator: Alpa A. Trivedi
Award Amount: $155,695.00
Abstract:
DESCRIPTION (provided by applicant): The goal of the Phase I research is to develop ex vivo gene therapy that will achieve long-term, localized delivery of human neurotrophin-3 (hNT-3) in the rat contusion model of spinal cord injury. Our overall goal is to develop cell-based… More

Novel Ex Vivo Gene Therapy for Spinal Cord Injury

Award Year / Program / Phase: 2003 / SBIR / Phase II
Agency: HHS
Principal Investigator: Alpa A. Trivedi
Award Amount: $749,980.00
Abstract:
DESCRIPTION (provided by applicant): There are approximately 10,000 traumatic spinal cord injuries in the United States each year. The average age of injury is 31 years. The majority (90%) of individuals survive and live near-normal life spans. Cost of treating these injuries is very high and does… More

NO-donor/SOD-mimetics for diabetic nephropathy

Award Year / Program / Phase: 2005 / SBIR / Phase I
Agency: HHS
Principal Investigator: Elwood E. Reynolds
Award Amount: $134,000.00
Abstract:
DESCRIPTION (provided by applicant): Vascular disease is the principal cause of morbidity and mortality in patients with diabetes, leading to nephropathy, retinopathy, neuropathy, and ischemic disease. Hyperglycemic damage to vascular endothelial cells is a major cause of these vascular… More

Human Sertoli Cell Model for Study of Male Reproductive Function and Toxicity

Award Year / Program / Phase: 2007 / SBIR / Phase I
Agency: HHS
Principal Investigator: Constance M. John
Award Amount: $255,200.00
Abstract:
DESCRIPTION (provided by applicant): The overall goal of the Phase I research is to develop a three-dimensional model of the blood-testis barrier (BTB) consisting of primary human Sertoli cells cultured on permeable membrane supports. The human Sertoli cel ls have been isolated from normal human… More

Preclinical Testing of Galectin-3C for Multiple Myeloma

Award Year / Program / Phase: 2008 / SBIR / Phase I
Agency: HHS
Principal Investigator: Constance M. John
Award Amount: $363,936.00
Abstract:
DESCRIPTION (provided by applicant): The overall goal is development of a novel human protein, Galectin-3C, as a treatment for multiple myeloma (MM) that can be given with other agents to increase the percentage of patients who are responsive to therapy, a nd the survival rate. MM is rarely curable… More

Model of the Human Testis for Reproductive Toxicology

Award Year / Program / Phase: 2011 / SBIR / Phase I
Agency: HHS
Principal Investigator: Constance M. John – 415-333-5570
Award Amount: $250,000.00
Abstract:
DESCRIPTION (provided by applicant): More than 87,000 chemicals have been developed and distributed over the past 50 years. The vast majority of these have not been tested for potential toxic effects in humans or animals. Most systematic toxicology research is conducted in animals and is very… More

Protein inhibitor of galectin-3 to limit fibrosis after myocardial infarction

Award Year / Program / Phase: 2013 / SBIR / Phase I
Agency: HHS
Principal Investigator: Constance M. John – (415) 333-5570
Award Amount: $299,958.00
Abstract:
DESCRIPTION (provided by applicant): The wound-healing response of the human body to injuries involves induction of fibrosis, which is a dynamic scarring process. When fibrosis occurs in internal organs, it is indisputably a major cause of morbidity and mortality worldwide. The overall goal of the… More